OPK — OPKO Health · catalysts, narrative & risks

Recent Catalysts (roughly Aug–Oct 2026)

Triggered conversion of 2029 convertible notes (Oct 1, 2026): OPKO announced that its 3.75% Convertible Senior Notes due 2029 (~$121 million outstanding) became convertible through Dec 31, 2026 after the share price exceeded 130% of the $1.15 conversion price. OPKO elected to settle conversions entirely in shares (noteholders receive 869.5652 shares per $1,000 principal), and the window may extend beyond year-end 2026. [2]

Labcorp sale of BioReference assets: OPKO agreed to sell select BioReference Health assets to Labcorp in a transaction worth up to $872 million (reported alternatively as $722 million upfront plus up to $150 million in earnout), intended to sharpen OPKO's biopharma focus and expand access to its 4Kscore test. [13] [14] [15]